Why strength training isn’t optional if you’re on a GLP-1 drug
GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — are genuinely remarkable. In clinical trials, semaglutide produced around 12% placebo-corrected weight loss, while tirzepatide achieved approximately 18%. For people who have struggled with weight for years, the results can feel life-changing.
But there is a significant catch that very few prescribing doctors are talking about — and it has nothing to do with nausea.
A meaningful portion of the weight you lose on these drugs is not fat. It’s muscle. And losing muscle sets off a cascade of consequences that can leave you lighter on the scale but physically weaker, more fragile, and at greater risk of serious injury than before you started.
The solution is straightforward. The research is clear. But it requires you to do something.
The muscle loss problem
When your body loses weight rapidly — whether through dieting, surgery, or medication — it doesn’t strip fat cleanly from your frame. It also breaks down lean tissue, which includes skeletal muscle.
Up to 40% of overall weight loss with semaglutide, and up to 25% with tirzepatide, is attributed to lean body mass. To put that in plain terms: if you lose 20kg on semaglutide, up to 8kg of that could come from muscle rather than fat.
In the STEP 1 trial evaluating semaglutide, lean mass was reduced by 6.92kg alongside a weight reduction of 15.2kg — meaning roughly 45% of total weight lost came from lean tissue.
This isn’t a minor side effect. Skeletal muscle is not just cosmetic tissue that gives you a toned appearance. It is the engine of your metabolism. Muscle burns calories at rest, stabilises your joints, keeps you upright, absorbs impact when you stumble, and protects your skeleton. When you lose it, you lose all of those functions simultaneously.
Emerging clinical evidence suggests that GLP-1 receptor agonists may exacerbate or precipitate sarcopenic obesity — a condition where someone has low muscle mass alongside excess body fat — particularly in older or frail individuals with limited muscular reserves.
From muscle loss to bone loss: the domino effect
Here is where the story becomes more serious, especially for anyone over 40.
Bone density is not fixed. Your skeleton is living tissue that constantly remodels itself in response to the mechanical stress placed on it. When your muscles contract and pull against your bones — during exercise, daily movement, or resistance training — they stimulate bone-forming cells called osteoblasts. Remove that stimulus, and bone resorption accelerates.
Research has found that bone loss is most pronounced at weight-bearing skeletal sites — the lumbar spine, total hip, and tibia — with no significant changes at non-weight-bearing areas. This suggests that mechanical unloading, rather than a direct drug effect, may be a key driver of bone resorption. This aligns with the mechanostat theory, which holds that bone adapts to changes in mechanical forces by modulating its own turnover rates.
In other words: less muscle means less mechanical load on your skeleton. Less load means your bones get the signal to shrink.
A 2026 study published in the Journal of Clinical Endocrinology & Metabolism found that semaglutide and tirzepatide use was associated with greater annualised total hip bone loss in patients without diabetes, with weight loss identified as the primary driver.
The FDA now notes in its label for semaglutide that it might increase the risk of bone fractures in older adults and women. Research presented at the American Academy of Orthopaedic Surgeons has also linked GLP-1 drugs to a potentially higher risk of osteoporosis — the condition that makes bones thin, brittle, and prone to fracturing from surprisingly minor incidents.
The scenario that matters most is a fall. A person in their 50s or 60s who has lost significant muscle and bone density during a year of GLP-1 treatment may step off a curb awkwardly, stumble on stairs, or slip getting out of the bath — and break a hip, wrist, or vertebra. The weight loss may have been real. The metabolic improvement may have been real. But the physical resilience that should have come with it wasn’t built.
What the research says about fixing this
Here is the good news, and it is backed by solid science: patients who engaged in structured resistance training 3–5 days per week while taking semaglutide or tirzepatide showed dramatically different body composition outcomes — with one case showing lean soft tissue actually increasing by 2.5% and another by 5.8%, even while losing significant overall body weight.
A prospective six-month study of 200 adults initiated on semaglutide or tirzepatide who received guidance on resistance training and protein intake showed they lost approximately 13% of their body weight but only about 3% of their muscle mass — a stark contrast to the 25–45% lean loss seen in clinical trials where exercise was not structured.
The mechanism is well understood. Resistance exercise creates mechanical tension in muscle fibres. That tension signals the body to preserve and build muscle protein, even in a caloric deficit. When you are eating less — which is exactly what GLP-1 drugs encourage — your body needs an overriding signal to hold onto muscle. Heavy resistance training provides that signal.
A 2025 review published in Current Opinion in Clinical Nutrition and Metabolic Care concluded that GLP-1 therapy for obesity should include resistance training, optimal protein intake, and if needed, specific nutrients to preserve muscle mass.
The same mechanical logic applies to bone. When muscles pull on bones during resistance training, bone mineral density is maintained and can even improve. This is why strength training is one of the most evidence-backed interventions for osteoporosis prevention — and why it becomes non-negotiable for anyone experiencing rapid weight loss.
What this means practically
If you are taking a GLP-1 medication, the weight loss is only half the work. The other half is protecting what’s underneath.
That means resistance training — not just walking, not just yoga, not just cardio. Exercises that challenge your muscles against load: pressing, pulling, squatting, hinging. Done consistently, 2–3 times per week at minimum, these movements send the biological signal that your muscles and bones need to stay.
The challenge is that most people on GLP-1 medications are experiencing reduced appetite, lower energy, and often nausea — especially in the early months. The idea of going to a conventional gym, figuring out what to lift, how much, and whether you’re doing it correctly, can feel overwhelming. Many people don’t start, or they start and stop.
This is precisely the problem that Threezero was built to solve.
Why Threezero is the ideal training partner for GLP-1 users
The Threezero Biocircuit delivers a complete strength and cardio workout in 30 minutes. The AI-driven Technogym circuit automatically adjusts to your current fitness level, sets the correct resistance, guides your range of motion, and progresses with you as you get stronger — without you having to think, wait, or guess.
For someone on a GLP-1 medication, this matters for specific reasons. Your energy levels may fluctuate. Your starting fitness level may be low. The last thing you need is an intimidating gym environment where you don’t know what to do. You need a structured, guided, time-efficient session that hits every major muscle group, challenges your skeleton, and gets you out in 30 minutes.
The science is unambiguous: the drugs do the fat loss. You have to do the muscle preservation. And the consequences of not doing so — sarcopenia, bone loss, and fragility fractures — are serious enough that this isn’t a suggestion. It’s a clinical imperative.
Your prescription is doing its job. Now it’s time to do yours.
Book a trial session at Threezero, Cape Quarter, De Waterkant. 30 minutes is all it takes.
This article is for informational purposes only and does not constitute medical advice. If you are taking GLP-1 medication, consult your prescribing doctor before starting any new exercise programme.
